CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabe...
July 01 2019 - 4:01PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that it will present an oral presentation
at the 55th Annual Meeting of the European Association for the
Study of Diabetes (EASD), taking place September 16 to 20, 2019, in
Barcelona, Spain.
Title: CRISPR-editing of hESCs
allows for production of immune evasive cells capable of
differentiation to pancreatic progenitors for future type 1
diabetes therapy (abstract #9, oral
presentation)Session: OP 02 – Looking ahead
towards better treatments for type 1 diabetesTime and
Date: Tuesday, September 17, 2019, at 10:15 AM - 11:45 AM
CESTLocation: Vilanova Hall
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer AG, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in London, United
Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Investor Contact:Susan
Kimsusan.kim@crisprtx.com
CRISPR Media Contact:Jennifer PaganelliWCG on
behalf of CRISPR347-658-8290jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024